Feed RGEN
RG

Repligen

RGEN · NASDAQ

$181.70 +2.52% (+$4.47)
1M +8.41%
Market Cap $10.0B
P/E Ratio 240.79x
Div. Yield -
ROE 1.98%

Bulios Fair Price

$137.21

24.5% downside

Trenutna cena

$181.7

Podcenjeno Poštena vrednost Precenjeno

Po podatkih Bulios Fair Price je delnica RGEN trenutno precenjena glede na svojo tržno ceno. Kako deluje?

Odkleni pošteno ceno

Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?

Analiza

AI poročilo o poslu, financah, vrednotenju, razpoloženju, novicah in tveganjih - napisano v nekaj minutah.

Piotroski F-Score Strong
7/9
Valuation
5 /100
Expensive
P/B 4.74x
P/S 12.74x
P/E 240.79x
Growth
31 /100
Declining
Book val. growth 3.30%
FCF growth 34.33%
EPS growth 35.73%
Profitability
64 /100
Moderate
FCF margin 14.11%
Op. margin 8.32%
Gross margin 51.05%
Quality
10 /100
Poor
Asset turnover 0.27x
ROA 1.41%
ROIC 1.83%
Debt
86 /100
Low
Net debt/EBITDA 0.69x
Int. coverage 3.50x
Debt/Equity 0.33x
Stability
42 /100
Moderate
Profitable years 1
EPS volatility 243.31%
Beta 1.05x

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o RGEN
Online

O podjetju

Repligen is an American company engaged in the development and production of materials used in the production of biological drugs. Based in Waltham, Massachusetts, the company was incorporated in Delaware in 1981. Repligen is a public company listed on the NASDAQ stock exchange under the symbol RGEN.

V vašem jeziku še ni na voljo, zato je besedilo v angleščini.

Sector

Healthcare

Industry

Medical - Instruments & Supplies

CEO

Olivier Loeillot

Employees

2,000

Headquarters

Waltham

Prihajajoči dogodki

03 NOV.

Earnings

Upcoming earnings report

30d

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.